Sbir phase II - topic 396 - imaging for cancer immunotherapies
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00015
- Awardee
-
Cellsight Technologies, Inc. UEI E3UQXACGFR43
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,995,174
Award facts
- Opportunity
-
- 75N91021R00068 Solicitation number
- Contract value 100% obligated
- $1,995,174.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94107, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,995,174 |
About this award
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellsight Technologies, Inc., a woman-owned small business. The $1,995,174 contract is for the development of an [18F]F-ARAG imaging agent to quantitatively assess response to immunotherapy in non-small cell lung cancer. This builds on a previous $300,000 SBIR Phase I contract from NCI to evaluate [18F]F-ARAG for predicting response to cancer immunotherapies. Cellsight Technologies also provides support services related to using [18F]F-ARAG to monitor cardiotoxicity associated with cancer treatments through subaward agreements. The contract has a firm fixed price pricing type and a completion date of September 15, 2026.
Quick answers
Who was awarded contract 75N91022C00015?
75N91022C00015 was awarded to Cellsight Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022C00015 worth?
The government has obligated $1,995,174 on 75N91022C00015.
Was contract 75N91022C00015 competed?
The extent of competition for 75N91022C00015 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award